The company has been adament about not doing a RS... the biggest news at this point we are looking for is the FDA approval for Orphan Drug Designation. The FDA is back logged and this approval is still in their hands. When that comes thru it will boost the PPS back to the 20 cent range.
As for the Feb deadline, its very customary for NASDAQ to approve two extensions when it comes to minimum BID... If there has been improvement and they can show that the Phase III trial will indeed start on time then they will most likely get the second extension. They really do not want to do a reverse split as it would be a hardship on the deal they signed to get Synworld to get China to approve crofelemer
These are great prices to enter if your a Pharma speculation buyer... as for the shorts, its been a field day for them, but it can turn into a nighmare for them if both Europe and the Orphan Drug are approved.
Market Data 
Markets 
AI
